Related Experiment Videos
[Chemosensitivity studies of urological malignancies]
T Uchibayashi1, H Hisazumi, M Egawa
1Department of Urology, School of Medicine, Kanazawa University.
Hinyokika Kiyo. Acta Urologica Japonica
|November 1, 1988
Summary
This study evaluated anticancer drug sensitivity in urological cancers using the human tumor clonogenic assay (HTCA). Results showed varying patient susceptibility to chemotherapy agents like vinblastine and cisplatin, indicating potential for personalized treatment strategies.
Area of Science:
- Oncology
- Pharmacology
- Urology
Background:
- Urological malignancies present a significant health challenge.
- Accurate prediction of chemosensitivity is crucial for effective cancer treatment.
Purpose of the Study:
- To assess the efficacy of the human tumor clonogenic assay (HTCA) in determining chemosensitivity for various urological cancers.
- To evaluate patient susceptibility to specific anticancer agents.
Main Methods:
- Utilized the human tumor clonogenic assay (HTCA) on surgical specimens from 67 patients with urological malignancies.
- Assessed chemosensitivity based on a >70% decrease in plating efficiency (Von Hoff's definition) or an in vivo-in vitro therapeutic index (TI) > 1.0.
Main Results:
- Adequate colonial growth for chemosensitivity testing was achieved in 30 out of 67 patients.
- Susceptibility to vinblastine (VBL) and cis-diamminedichloroplatinum (CDDP) varied across renal, urothelial, and testicular cancers.
- Adriamycin (ADM) also demonstrated differential efficacy among patient groups.
Conclusions:
- The HTCA is a viable method for evaluating chemosensitivity in urological malignancies.
- Individualized drug susceptibility profiles can be generated, potentially guiding treatment decisions for urological cancer patients.